Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABUS vs SDG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABUS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

ABUS Overall Winner 6-Pillar Tally: ABUS 6 – 0 SDG Matrix Metrics: ABUS 8 – 2 SDG

As of Nov 16, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over iShares Trust iShares MSCI Global Sustainable Development Goals ETF (SDG) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABUS carries a Unified Composite Score of 56.3/100 (HOLD) at $4.04 (10.2x Forward P/E, 80.1% operating margin), whereas SDG carries 45.9/100 (HOLD) at $85.63 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ABUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.8); meanwhile SDG is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABUS vs SDG
ABUS NASDAQ Head-to-Head Winner
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.04
-1.22% 1D
Market Cap $627.0M
TTM Revenue $181M
Forward P/E 10.2x
Beta / 30D Vol 1.20β · 51% Vol
Unified Composite Score
56.3 / 100 HOLD
Tech 72.0 Fund 65.0 Flow 68.0 Mom 53.7
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.8 · SMA20: $4.05 · SMA50: $4.44
SDG NASDAQ
iShares Trust iShares MSCI Global Sustainable Development Goals ETF
Institutional Equity
$85.63
-0.81% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.84β · 15% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 38.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.6%) with fading momentum, RSI 41
RSI-14: 40.5 · SMA20: $86.99 · SMA50: $87.70

6-Pillar Scorecard Institutional Category Breakdown (ABUS 6 – 0 SDG)

Columns: Metric · ABUS · SDG
1. Valuation Multiples ABUS
Forward P/E 10.2x N/M
Trailing P/E 3.6x N/M
PEG Ratio N/M N/M
EV / Revenue 2.0x N/M
2. Growth & Scale ABUS
Revenue Growth (YoY) -43.5% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $181M N/A
Market Cap $627.0M N/A
3. Profitability & Quality ABUS
Gross Margin 91.9% N/A
Operating Margin 80.1% N/A
Net Profit Margin 121.2% N/A
Return on Equity (ROE) 269.6% N/A
4. Balance Sheet & Cash Flow ABUS
Cash Generation (TTM) $221M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $264M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABUS
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.9% (28th %ile) N/A (N/A)
Put/Call OI Skew 0.18x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat ABUS
OpEx & R&D Intensity 11.8% of Rev ($21M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABUS (8) vs SDG (2)
Institutional Metric ABUS SDG Criterion Row Edge
Market Capitalization
Scale
$627.0M N/A Larger Scale ABUS
Trailing P/E Ratio
Valuation
3.6x N/M Lower Multiple ABUS
Forward P/E Ratio
Valuation
10.2x N/M Lower Multiple ABUS
Revenue Growth (YoY)
Growth
-43.5% N/A Higher Growth ABUS
Operating Margin (TTM)
Profitability
80.1% N/A Higher Margin ABUS
Net Profit Margin
Profitability
121.2% N/A Higher Margin ABUS
Return on Equity (ROE)
Capital Efficiency
269.6% N/A Higher ROE ABUS
52-Week Range Position
Momentum
28% ($4–$5) 38% ($80–$94) Stronger Trend SDG
Beta / 30D Volatility
Risk Regime
1.20β · 51% Vol 0.84β · 15% Vol Lower Realized Risk SDG
Unified Institutional Score
Composite Signal
56.3 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite ABUS
Trailing 12M Revenue (USD)
Operating Scale
$181M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
91.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$221M ($264M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SDG +3.96 pp
ABUS: -4.27% · SDG: -0.31%
3M Horizon SDG +9.67 pp
ABUS: -16.53% · SDG: -6.86%
6M Horizon ABUS +1.35 pp
ABUS: -3.12% · SDG: -4.47%
1Y Horizon SDG +11.46 pp
ABUS: -11.4% · SDG: +0.06%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABUS vs SDG. Trailing 12-month operating profitability (ABUS 80.1% vs SDG N/A) and valuation multiples (ABUS 10.2x vs SDG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$181M
Gross Margin91.9%
Op. Margin80.1%
ROE / Fwd P/E269.6% · 10.2x
SDG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABUS CONSOLIDATION
92d in phase · OBV ACCUMULATION
Current IV 72.9%
IV Percentile 28th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact ABUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SDG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SDG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABUS Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $627.0M market capitalization and 80.1% operating margin.
OpEx & R&D Reinvestment 11.8% of Rev ($21M)
90D Engineering Disclosures 0 Published
SDG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABUS vs SDG Key Questions & Quantitative Answers

As of Nov 16, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over iShares Trust iShares MSCI Global Sustainable Development Goals ETF (SDG) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABUS carries a Unified Composite Score of 56.3/100 (HOLD) at $4.04 (10.2x Forward P/E, 80.1% operating margin), whereas SDG carries 45.9/100 (HOLD) at $85.63 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ABUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.8); meanwhile SDG is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABUS leads the Growth & Scale pillar: ABUS posts -43.5% YoY revenue growth and +0.0% YoY earnings growth on $181M TTM revenue (91.9% gross margin, 80.1% operating margin), compared with SDG at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABUS generates $181M in USD-normalized revenue versus N/A for SDG. In operating R&D and SG&A reinvestment, ABUS deploys 11.8% of Rev ($21M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SDG.

ABUS screens cheaper on headline valuation multiples. ABUS trades at 10.2x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (unreported FCF margin), whereas SDG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABUS (269.6% ROE) versus SDG (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ABUS carries 72.9% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.20β · 51% Vol realized risk). By comparison, SDG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 15% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

iShares Trust iShares MSCI Global Sustainable Development Goals ETF (SDG) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.